GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Newron Pharmaceuticals SpA (XTER:NP5) » Definitions » Gross Profit

Newron Pharmaceuticals SpA (XTER:NP5) Gross Profit : €6.97 Mil (TTM As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Newron Pharmaceuticals SpA Gross Profit?

Newron Pharmaceuticals SpA's gross profit for the six months ended in Jun. 2024 was €3.41 Mil. Newron Pharmaceuticals SpA's gross profit for the trailing twelve months (TTM) ended in Jun. 2024 was €6.97 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Newron Pharmaceuticals SpA's gross profit for the six months ended in Jun. 2024 was €3.41 Mil. Newron Pharmaceuticals SpA's Revenue for the six months ended in Jun. 2024 was €3.41 Mil. Therefore, Newron Pharmaceuticals SpA's Gross Margin % for the quarter that ended in Jun. 2024 was N/A%.

Newron Pharmaceuticals SpA had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage

During the past 13 years, the highest Gross Margin % of Newron Pharmaceuticals SpA was 94.39%. The lowest was 65.92%. And the median was 84.01%.


Newron Pharmaceuticals SpA Gross Profit Historical Data

The historical data trend for Newron Pharmaceuticals SpA's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Newron Pharmaceuticals SpA Gross Profit Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.61 4.96 5.76 6.09 9.06

Newron Pharmaceuticals SpA Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.83 3.26 5.49 3.56 3.41

Competitive Comparison of Newron Pharmaceuticals SpA's Gross Profit

For the Biotechnology subindustry, Newron Pharmaceuticals SpA's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Newron Pharmaceuticals SpA's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's Gross Profit distribution charts can be found below:

* The bar in red indicates where Newron Pharmaceuticals SpA's Gross Profit falls into.



Newron Pharmaceuticals SpA Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Newron Pharmaceuticals SpA's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=9.057 - 0
=9.06

Newron Pharmaceuticals SpA's Gross Profit for the quarter that ended in Jun. 2024 is calculated as

Gross Profit (Q: Jun. 2024 )=Revenue - Cost of Goods Sold
=3.407 - 0
=3.41

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €6.97 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Newron Pharmaceuticals SpA's Gross Margin % for the quarter that ended in Jun. 2024 is calculated as

Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=3.41 / 3.407
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Newron Pharmaceuticals SpA  (XTER:NP5) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Newron Pharmaceuticals SpA had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage


Newron Pharmaceuticals SpA Gross Profit Related Terms

Thank you for viewing the detailed overview of Newron Pharmaceuticals SpA's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Newron Pharmaceuticals SpA Business Description

Traded in Other Exchanges
Address
Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of therapies for patients with diseases of the central and peripheral nervous system. Geographically the research and development activities are performed in Italy and the United States.
Executives
Stefan Weber Board of Directors
Dr. Ulrich Köstlin Supervisory Board

Newron Pharmaceuticals SpA Headlines

No Headlines